The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Open accessAbstract
Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P < .001 between groups) and from 29.9% to 46.4% (P < .001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing. Trial Registration: ClinicalTrials.gov identifier: NCT02597127.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials demonstrate that LDL-C levels decrease by 50% and maintain this reduction for at least 18 months of treatment [25, 26].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-1 biannual 300 mg dosing regimen maintained a 46.4% LDL-C reduction from Day 1 and Day 90 through Day 360 [25].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies presented demonstrated sustained maximum LDL-C reduction levels that persisted throughout six months following the last administered dose [25, 42, 70].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.02.004 · Cited by 688
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Navar‐Boggan, A. M., Peterson, E. D., D’Agostino, R. B., Neely, B., Sniderman, A. D., & Pencina, M. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012477 · Cited by 412
Cited by
Sorted by citations
Items 101–172 of 172
Rajtar-Salwa, R., Bobrowska, B., Socha, S., Dziewierz, A., Siudak, Z., Batko, J., Bartuś, S., & Krawczyk‐Ożóg, A. (2024) · Medicina · doi:10.3390/medicina60071124 · Cited by 10
“For instance, in the ORION-1 study, a single 300 mg dose of inclisiran was shown to decrease LDL-C by 38.4% at 180 days post-administration, and a two-dose regimen resulted in a 52.6% reduction [26], with these decreases being maintained over time [27].”
BackgroundInfluentialDuprez, D. A., Handelsman, Y., & Koren, M. J. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s261719 · Cited by 8
Ray, K. K., Gunn, L. H., Conde, L. G., Raal, F. J., Wright, R. S., Gosselin, N. H., Leiter, L. A., Köenig, W., Schwartz, G. G., & Landmesser, U. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117472 · Cited by 8
Self-citationLDL cholesterol: lower, faster, younger?
Berberich, A. J., & Hegele, R. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30389-4 · Cited by 7
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
“The treatment with inclisiran every 6 months resulted in durable LDL-C level reductions over 1 year [23].”
MethodLi, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
“During the administration of Inclisiran, injection site reactions, discomfort, erythema, rash, and other symptoms were observed [24,28].”
Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies
Gao, R., Liu, M., Yang, H., Shen, Y., & Xia, N. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1548355 · Cited by 6
Targeting LDL cholesterol: Early treatment is key to population health
Stock, J. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.013 · Cited by 6
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“The studies presented demonstrated sustained maximum LDL-C reduction levels that persisted throughout six months following the last administered dose [25, 42, 70].”
InfluentialTreatment of heterozygous familial hypercholesterolemia: what does the future hold?
Polychronopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839417 · Cited by 5
Cequier, A. R., Arrarte, V., Campuzano, R., Castro, A., Cordero, A., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., de Sá, E. L., Núñez, J. E., et al. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.017 · Cited by 5
Donis, N., Jiang, Z., D'Emal, C., Hulin, A., Debuisson, M., Dulgheru, R., Nguyen, M.-L., Postolache, A., Lallemand, F., Coucke, P. A., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.839720 · Cited by 5
Zou, D., Hu, Q., Liu, Y., & Yu, L. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01784-0 · Cited by 5
“Current studies have shown that the efficacy of inclisiran does not rely on blood concentration [20], and that there are no differences in efficacy between genders or under conditions like hepatic or renal impairment [20–23].”
The Munich Meeting: Medical Maturation, More Mechanisms, and Milasen
Aartsma-Rus, A. M., & Watts, J. K. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.29003.aar · Cited by 5
“Examples highlighted at the meeting included phase 3 trials of givosiran and inclisiran, both siRNAs targeting aminolevulinic acid synthase (ALAS1) and proprotein convertase subtilisin-kexin type 9 (PCSK9), respectively [4,5].”
Tsamoulis, D., Rallidis, L. S., & Kosmas, C. E. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2360415 · Cited by 4
“ORION-1 1-year follow-up (2019) [42] ∼ 50% reduction at 6 months and ∼ 30% reduction at 12 months.”
BackgroundEfficacy, benefit and safety of inclisiran
López-Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100730 · Cited by 4
Wang, S.-W., Li, L.-C., Fu, C.-M., Lee, Y.-T., Kuo, H., & Hsu, C.-N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.887915 · Cited by 5
Personalization of Treatment is the Way Forward in Care and Trials
Esserman, L. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0604 · Cited by 4
“Surrogates are still being used to rapidly test promising new therapeutic advances in cardiology to avoid death from fatal heart attack (5).”
BackgroundLupi, A., Baluci, M., Persampieri, S., Perversi, I., Presutti, D. G., Somaschini, A., Gaudio, G. V., Guasti, L., Ferrini, M., Corsini, A., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.005 · Cited by 3
“By significantly reducing LDL-C levels within days, inclisiran effectively contributed to filling this critical therapeutic gap, offering the potential to improve outcomes and better protect patients during this vulnerable period [29].”
Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins
Brandts, J., Verket, M., Zambon, A., Marx, N., Müller-Wieland, D., & Federici, M. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03166-4 · Cited by 3
“Inclisiran, a small interfering RNA targeting PCSK9 administered every six months (two injections per year), offers sustained LDL-C reductions of approximately 50% [49] regardless of glycemic status or body-mass-index (BMI) [50].”
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Rakočević, J., Dobric, M. R., Vučić, R. M., Furtula, M., Zaletel, I. V., Milutinović, K., Ilijevski, A., Labudović‐Borović, M., Tomasevic, M. V., & Bajčetić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066012 · Cited by 5
“The safety profile of inclisiran was comparable to previously published results [24,30].”
BackgroundResultInfluentialFamilial hypercholesterolemia: current status of the problem, treatment, and prevention
Bliznyuk, S. А., Bubnova, M. G., & Владиславович, Е. М. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2532 · Cited by 4
Ference, B. A., Ference, T. B., Catapano, A. L., Nicholls, S. J., & Ray, K. K. (2024) · medRxiv · doi:10.1101/2024.06.30.24309740 · Cited by 3
Self-citationCardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 2
“Post hoc analyses in post-myocardial infarction populations have reinforced its potential role in secondary prevention, although outcome data on MACE are still awaited from the ongoing ORION-4 trial [4,25–27].”
Platform Assessment of Concentration–QTc Relationship Across GalNAc–siRNA Molecules
Badri, P. S., Kolachana, K., Duong, A., Lasko, M. J., Nandi, T., Mehrotra, N., & Robbie, G. J. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01606-0 · Cited by 2
“More importantly, GalNAc–siRNAs have not demonstrated any propensity to prolong the QTc interval, and there have been no torsades de pointes events in clinical studies across the platform [6, 29, 33–35].”
Lu, F., Li, E., & Yang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1413123 · Cited by 2
Recent progress in anti-atherosclerosis strategies and prospective therapeutic targets
Wang, Z., He, X., Bai, H., Feng, D., Qu, Y., Zhang, Y., Lee, R. J., & Sun, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126122 · Cited by 4
Chin, D. D., Poon, C. J., Wang, J., Joo, J., Ong, V., Jiang, Z., Cheng, K., Plotkin, A., Magee, G. A., & Chung, E. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.290361 · Cited by 2
Zhao, J., Tong, X., Peng, J., Lyu, C., & Lu, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2503094 · Cited by 1
Dey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1
“90 Importantly, these reductions have been sustained over the long term, with follow-up studies demonstrating consistent efficacy in maintaining lowered LDL cholesterol levels over extended periods.”
BackgroundEficacia, beneficio y seguridad de inclisiran
López‐Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.003 · Cited by 2
Cancer therapeutics hope: microRNA clinical practice and perspectives
Ye, C., & Zheng, J. (2025) · Visualized Cancer Medicine · doi:10.1051/vcm/2025007 · Cited by 1
“Recently, the siRNA-derived drug inclisiran has successfully completed phase II clinical trials and safety evaluations, demonstrating remarkable ef fi cacy [22 – 24].”
Centola, A., Carbonara, M., Nuzzo, S. D., Cuculo, A., Ruggiero, A., Campanale, G., Iacoviello, M., Gargiulo, P., Filardi, P. P., & Brunetti, N. D. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.001 · Cited by 1
“In ORION 1 study, 501 patients were studied; after 180 days, a reduction in LDL-c was observed from 27.9 to 41.9 % after a single dose of inclisiran and from 35.5 to 52.6 % after two doses [9].”
InfluentialBreaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
Huang, S.-J., Huang, P. H., Song, N.-N., Jia, X.-H., Gao, H., Lu, Z., & Wen, X. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105003 · Cited by 1
Patient Preferences for Lipid-Lowering Agents in Hypercholesterolemia: A Discrete Choice Experiment
Yiu, H. H. E., Yan, V. K. C., Au, C. C. L., Deng, E. K., Wong, M. C. S., Yan, B. P., Wong, W. C. W., Liu, S. Y., Wong, C. K., Chan, E. W., et al. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101662 · Cited by 1
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_14 · Cited by 1
Inclisiran: new era of lipid-lowering therapy?
Beneš, J. (2023) · Cor et Vasa · doi:10.33678/cor.2022.043 · Cited by 1
“LDL cholesterol-lowering effect of inclisiran is reversed at the rate of approximately 2% per month, so it can persist up to approximately two years.(24,25) This mechanism of action is completely different than contemporarily used monoclonal antibodies (evolocumab, alirocumab).”
BackgroundGenetic Risk Score Enables a Vaccine for Early Primary Prevention of CAD
Roberts, R. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1617 · Cited by 1
Behandlungsoptionen bei schweren Hypercholesterinämien
Vogt, A. (2019) · CardioVasc · doi:10.1007/s15027-019-1672-4 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 2
“Early studies show that inclisiran is well tolerated and efficacious in lowering LDL-C by up to 60% but only requiring 6-monthly dosing as opposed to fortnightly/monthly for PCSK9 antibodies [30].”
BackgroundPCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection
Pandey, P., Zhao, C., & Liu, B. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_12 · Cited by 1
Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease
Mahajan, K., & Chandra, K. S. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620943020 · Cited by 1
Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Vogt, A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-4373-0 · Cited by 1
Atherosclerotic cardiovascular diseases and clinical significance of treatment with inclisiran
Blaha, V. (2021) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.011 · Cited by 1
Pairwise genetic interactions modulate lipid plasma levels and cellular uptakePreprint
Zimoń, M., Huang, Y., Trasta, A., Liu, J. Z., Chen, C., Halavatyi, A. A., Blattmann, P., Klaus, B., Whelan, C. D., Sexton, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.29.360818
Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
Winkler, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822258-4.00010-9
Inclisirán as an alternative treatment for Hypercholesterolemia
Villota, J. A. O., Martínez, J. A. P., de Moya, L. A. B., Vega, R. A. C., Valencia, R. R., Medina, L. M. M., Rodriguez, M., & Castillo, I. T. P. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.12.3.0694
Inclisiran — lipid-lowering drug using RNA therapy. Hypolipidemic potential
Sumarokov, A. M. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221704132
Inclisiran - hope in the fight against dyslipidemia
KRAWIEC, P., MADEJ, K., WOLANIN, I., ZIELONKA, B., KOWALCZYK, I., STACHYRA, B., WOLANIN, M., STAWIKOWSKI, C., Dengler, B., & Osińska, A. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.27.01.001 · Cited by 1
Brandts, J., & Ray, K. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00021-2
Self-citationToth, P. P., Rizzo, M., & Banach, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_27
Familial hypercholesterolaemia: a genetic condition with associated cardiovascular risk
Neves, E., Bueser, T. ‘., Frampton, K., Lee, E. J., Studart, D., Tobin, L., & Wilson, E. M. (2024) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2023.0024
Clinical Follow-Up of Patients after Coronary Artery Bypass Grafting
Oliveira, J. C. (2024) · Cardiology and cardiovascular medicine. · doi:10.5772/intechopen.113939
Lipidmanagement bei Typ-2-Diabetes mellitus – Strategien zur Risikoreduktion
Brandts, J. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2317-4226
Singareddy, S., Dhakal, S., Limbaña, T. A., Murugan, V., Nazmin, F., Garcia, J., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.69918
“According to study results, around 90%-100% of the subjects in the single dose group and 96.6%-100% in the double dose groups have not returned to levels 20% within the baseline at day 180, which dropped to 60.0%-75.0% and 69.5%-86.3% of those receiving single or double dose, respectively [13].”
BackgroundResultInfluentialLipidmanagement bei Typ-2-Diabetes mellitus
Brandts, J. (2024) · Diabetes aktuell · doi:10.1055/a-2401-3884
Lipid lowering with inclisiran: a single-center experience from Slovakia
Tóth, Š., Vachalcová, M., Jarolimkova, A., Sevcik, M., & Porubän, T. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.017
Protection from malaria infection using liver-targeted siRNA
Steel, R. W. J., Schepis, A., Nguyen, T. K. T., Milstein, S., Yucius, K., Tu, H. C., Fishilevich, E., Haslett, P. A. J., & Kappe, S. H. I. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101516
“Of note, while durable knockdowns have been shown in clinical setting, 19,22,23 we cannot exclude that the liver infection reduction was instead caused by the immune response to sporozoites generated by the first challenge.”
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
刘, 美. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113273
Boyadjian, O., Ebrahimian, T., O'Connor, J. M., Rak, J. W., Lehoux, S., & Tabrizian, M. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202526604
Nusantara, A. C. P., Rapsanjani, A. D., Handirosiyanto, I., Mandiricha, T., & Gaffar, A. S. (2026) · International Journal of the Cardiovascular Academy · doi:10.4274/ijca.2026.53315
Étude de l’influence de la glutaminolyse des macrophages dans les maladies cardio-métaboliques
Merlin, J. (2020) · theses.fr (ABES) · doi:10.70675/68e10f28zf840z48bfz9bacz5511a3a2b208
Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
Ramin‐Mangata, S. (2020) · theses.fr (ABES) · doi:10.70675/26622ba5zb0fcz4d30za6e6z5c95a0b5a33d
Liu, Z., Liu, R., Ying, Y., & Nie, J. (2026) · Biomedicines · doi:10.3390/biomedicines14051142
“…systematically established its efficacy: the phase 2 ORION-1 trial demonstrated durable LDL-C reductions with infrequent dosing over 6–12 months [92]; ORION-9 confirmed significant LDL-C lowering versus placebo in adults with heterozygous familial hypercholesterolaemia (HeFH) [89]; and the…”
Inclisiran—will it fulfill its promise?
Zadeh, S. S. T., Fogacci, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104848
Granata, L. G., Giubilato, S., Campanella, F., Amico, F., Fusco, S. A. D., & Colivicchi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1886347
Bal, H. S., Pampana, A., Ranjan, P., Nayak, A., Yerabolu, K., Patel, H., Vekariya, N., Crowley, M. R., Li, P., Arora, G., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101804
Wu, X., & Zhang, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm48237
“The one-year follow-up results of the ORION-1 clinical trial [24] indicated that two 300 mg doses on day 1 and day 90 sustained a 50% reduction in LDL-C levels for up to 6 months.”
Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD
Roberts, R., & Roberts, M. (2026) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1851
Causas y evolución del colesterol LDL tras la suspensión del inclisirán en prevención secundaria
González, E. F., Matos, F. R., Piro, V., Marco, M. D. V. G., Ruíz, M. G., & Quintana, A. G. (2026) · REC CardioClinics · doi:10.1016/j.rccl.2026.09.003
Metadata
- Authors
- Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Charing Cross Hospital (GB)
- Medicines Company (United States) (US)
- Saga University (JP)
- University of Toronto (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Mayo Clinic (US)
- University of Amsterdam (NL)
- Corresponding author
- Ray, Kausik K.
- ORCID
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-11-01
- Volume
- 4
- Issue
- 11
- Pages
- 1067
- ISSN
- 2380-6583 (ISSN-L)
- PMC
- PMC6763983
- OpenAlex
- W2976144989
- Cited by
- 172
- References
- 17
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 33 · 2023: 25 · 2022: 19 · 2021: 20 · 2020: 34 · 2019: 5
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Cardiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, LDL cholesterol, PCSK9, siRNA, single-dose regimen, dosing frequency, statin-resistant hypercholesterolemia, lipid-lowering therapy, PCSK9 inhibition, patient adherence, familial hypercholesterolemia, atherosclerotic cardiovascular disease
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Severity of Illness Index, Time Factors, Treatment Outcome, Risk Assessment, RNA, Small Interfering, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
